Robust Matrix Estimation with Side Information
利用辅助信息的稳健矩阵估计AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要明确将块缺失结构联系到因果面板数据,并讨论烟草销售应用中的处理效应估计,因此选择面板数据与因果推断。
利用辅助信息的稳健矩阵估计AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
We introduce a flexible framework for high-dimensional matrix estimation to incorporate side information for both rows and columns. Existing approaches, such as inductive matrix completion, often impose restrictive structure-for example, an exact low-rank covariate interaction term, linear covariate effects, and limited ability to exploit components explained only by one side (row or column) or by neither-and frequently omit an explicit noise component. To address these limitations, we propose to decompose the underlying matrix as the sum of four complementary components: (possibly nonlinear) interaction between row and column characteristics; row characteristic-driven component, column characteristic-driven component, and residual low-rank structure unexplained by observed characteristics. By combining sieve-based projection with nuclear-norm penalization, each component can be estimated separately and these estimated components can then be aggregated to yield a final estimate. We derive convergence rates that highlight robustness across a range of model configurations depending on the informativeness of the side information. We further extend the method to partially observed matrices under both missing-at-random and missing-not-at-random mechanisms, including block-missing patterns motivated by causal panel data. Simulations and a real-data application to tobacco sales show that leveraging side information improves imputation accuracy and can enhance treatment-effect estimation relative to standard low-rank and spectral-based alternatives.